AMPH
Amphastar Pharmaceuticals, Inc.
Price Chart
Latest Quote
$27.92
Current Price| Previous Close | $26.49 |
| Open | $26.36 |
| Day High | $28.13 |
| Day Low | $26.34 |
| Volume | 433,403 |
Stock Information
| Shares Outstanding | 45.95M |
| Total Debt | $656.77M |
| Cash Equivalents | $276.21M |
| Revenue | $723.31M |
| Net Income | $111.63M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.30B |
| P/E Ratio | 12.35 |
| EPS (TTM) | $2.26 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 26/42| Debt to Equity | 0.89 |
| Debt to Earnings | 1.74 |
| Current Ratio | 3.07 |
| Quick Ratio | 2.07 |
| Avg Revenue Growth | 16.80% |
| Profit Margin | 21.79% |
| Return on Equity | 21.78% |
| Avg FCF Growth | 36.08% |
| FCF Yield | 13.28% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $27.92 | 444,100 |
| 2026-01-30 | $26.49 | 294,500 |
| 2026-01-29 | $26.15 | 184,400 |
| 2026-01-28 | $26.12 | 209,000 |
| 2026-01-27 | $26.25 | 264,500 |
| 2026-01-26 | $26.60 | 316,200 |
| 2026-01-23 | $25.92 | 269,500 |
| 2026-01-22 | $26.15 | 233,300 |
| 2026-01-21 | $26.22 | 251,600 |
| 2026-01-20 | $25.95 | 282,600 |
| 2026-01-16 | $26.07 | 286,900 |
| 2026-01-15 | $26.00 | 584,100 |
| 2026-01-14 | $27.76 | 472,400 |
| 2026-01-13 | $28.91 | 345,600 |
| 2026-01-12 | $29.40 | 455,700 |
| 2026-01-09 | $27.74 | 247,200 |
| 2026-01-08 | $27.74 | 304,400 |
| 2026-01-07 | $27.33 | 342,800 |
| 2026-01-06 | $27.62 | 300,100 |
| 2026-01-05 | $26.72 | 419,200 |
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
đ° Latest News
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
StockStory âĸ 2026-01-15T20:46:10Z
A Look At Amphastar Pharmaceuticals (AMPH) Valuation After The AMP-110 License Agreement With Nanjing Hanxin
Simply Wall St. âĸ 2026-01-15T20:09:07Z
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead
StockStory âĸ 2026-01-15T04:04:34Z
Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth
MarketBeat âĸ 2026-01-14T23:23:20Z
1 Profitable Stock Worth Your Attention and 2 Facing Headwinds
StockStory âĸ 2026-01-14T04:32:58Z
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
StockStory âĸ 2026-01-12T21:05:49Z
The Bull Case For Amphastar Pharmaceuticals (AMPH) Could Change Following New BofA Coverage And JPM Spotlight
Simply Wall St. âĸ 2026-01-11T05:10:20Z
3 Low-Volatility Stocks We Find Risky
StockStory âĸ 2026-01-08T04:42:15Z
Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says
MT Newswires âĸ 2026-01-07T16:21:14ZAmphastar Director Sells 16,679 Shares for $441,800
Motley Fool âĸ 2025-12-23T15:07:27Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $358,112,000 | $293,274,000 | $250,127,000 | $238,029,000 |
| Cost Of Revenue | $358,112,000 | $293,274,000 | $250,127,000 | $238,029,000 |
| Total Revenue | $731,967,000 | $644,395,000 | $498,987,000 | $437,768,000 |
| Operating Revenue | $712,814,000 | $593,238,000 | $498,987,000 | $437,768,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $30,343,000 | $27,158,000 | $1,846,000 | $885,000 |
| Total Expenses | $526,548,000 | $447,408,000 | $391,490,000 | $367,881,000 |
| Other Income Expense | $4,076,000 | $-3,929,000 | $9,068,000 | $14,536,000 |
| Other Non Operating Income Expenses | $4,076,000 | $-3,929,000 | $9,068,000 | $14,536,000 |
| Net Non Operating Interest Income Expense | $-19,731,000 | $-21,699,000 | $-525,000 | $-284,000 |
| Interest Expense Non Operating | $30,343,000 | $27,158,000 | $1,846,000 | $885,000 |
| Operating Expense | $168,436,000 | $154,134,000 | $141,363,000 | $129,852,000 |
| Selling And Marketing Expense | $37,802,000 | $28,853,000 | $21,531,000 | $17,486,000 |
| General And Administrative Expense | $56,720,000 | $51,540,000 | $45,061,000 | $51,434,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $159,519,000 | $137,545,000 | $91,386,000 | $62,116,000 |
| Net Interest Income | $-19,731,000 | $-21,699,000 | $-525,000 | $-284,000 |
| Interest Income | $10,612,000 | $5,459,000 | $1,321,000 | $601,000 |
| Normalized Income | $159,519,000 | $137,545,000 | $91,386,000 | $62,116,000 |
| Net Income From Continuing And Discontinued Operation | $159,519,000 | $137,545,000 | $91,386,000 | $62,116,000 |
| Total Operating Income As Reported | $205,419,000 | $196,987,000 | $107,497,000 | $69,887,000 |
| Net Income Common Stockholders | $159,519,000 | $137,545,000 | $91,386,000 | $62,116,000 |
| Net Income | $159,519,000 | $137,545,000 | $91,386,000 | $62,116,000 |
| Net Income Including Noncontrolling Interests | $159,519,000 | $137,545,000 | $91,386,000 | $63,301,000 |
| Net Income Continuous Operations | $159,519,000 | $137,545,000 | $91,386,000 | $63,301,000 |
| Earnings From Equity Interest Net Of Tax | $-573,000 | $-1,981,000 | $-1,177,000 | $-208,000 |
| Pretax Income | $189,764,000 | $171,359,000 | $116,040,000 | $84,139,000 |
| Interest Income Non Operating | $10,612,000 | $5,459,000 | $1,321,000 | $601,000 |
| Operating Income | $205,419,000 | $196,987,000 | $107,497,000 | $69,887,000 |
| Gross Profit | $373,855,000 | $351,121,000 | $248,860,000 | $199,739,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $3.06 | $2.60 | $1.74 | $1.25 |
| Basic EPS | $3.29 | $2.85 | $1.88 | $1.30 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $277,312,000 | $240,294,000 | $146,161,000 | $111,557,000 |
| Reconciled Depreciation | $57,205,000 | $41,777,000 | $28,275,000 | $26,533,000 |
| EBITDA (Bullshit earnings) | $277,312,000 | $240,294,000 | $146,161,000 | $111,557,000 |
| EBIT | $220,107,000 | $198,517,000 | $117,886,000 | $85,024,000 |
| Diluted Average Shares | $52,058,000 | $53,001,000 | $52,427,000 | $49,784,000 |
| Basic Average Shares | $48,429,000 | $48,265,000 | $48,551,000 | $47,777,000 |
| Diluted NI Availto Com Stockholders | $159,519,000 | $137,545,000 | $91,386,000 | $62,116,000 |
| Tax Provision | $29,672,000 | $31,833,000 | $23,477,000 | $20,630,000 |
| Research And Development | $73,914,000 | $73,741,000 | $74,771,000 | $60,932,000 |
| Selling General And Administration | $94,522,000 | $80,393,000 | $66,592,000 | $68,920,000 |
| Other Gand A | $56,720,000 | $51,540,000 | $45,061,000 | $51,434,000 |
| Minority Interests | - | $0 | $0 | $-1,185,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $141,638,000 | $26,126,000 | $491,360,000 | $406,652,000 |
| Total Assets | $1,577,470,000 | $1,512,912,000 | $741,987,000 | $671,529,000 |
| Total Non Current Assets | $1,043,399,000 | $1,023,312,000 | $363,668,000 | $353,410,000 |
| Other Non Current Assets | $25,992,000 | $25,910,000 | $20,856,000 | $16,665,000 |
| Non Current Deferred Assets | $71,124,000 | $53,252,000 | $38,527,000 | $22,399,000 |
| Non Current Deferred Taxes Assets | $71,124,000 | $53,252,000 | $38,527,000 | $22,399,000 |
| Goodwill And Other Intangible Assets | $590,660,000 | $613,295,000 | $37,298,000 | $38,870,000 |
| Other Intangible Assets | $587,611,000 | $610,079,000 | $34,172,000 | $35,557,000 |
| Current Assets | $534,071,000 | $489,600,000 | $378,319,000 | $318,119,000 |
| Other Current Assets | $18,214,000 | $9,057,000 | $7,563,000 | $7,274,000 |
| Restricted Cash | $2,435,000 | $2,435,000 | $2,435,000 | $2,435,000 |
| Inventory | $153,741,000 | $105,833,000 | $103,584,000 | $92,807,000 |
| Receivables | $138,036,000 | $115,469,000 | $88,975,000 | $78,930,000 |
| Taxes Receivable | $1,747,000 | $526,000 | $171,000 | $126,000 |
| Accounts Receivable | $136,289,000 | $114,943,000 | $88,804,000 | $78,804,000 |
| Allowance For Doubtful Accounts Receivable | $-3,500,000 | $-2,800,000 | $-2,700,000 | $-2,300,000 |
| Gross Accounts Receivable | $139,789,000 | $117,743,000 | $91,504,000 | $81,104,000 |
| Cash Cash Equivalents And Short Term Investments | $221,645,000 | $256,806,000 | $175,762,000 | $136,673,000 |
| Cash And Cash Equivalents | $151,609,000 | $144,296,000 | $156,098,000 | $126,353,000 |
| Prepaid Assets | - | - | - | $7,274,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $450,255,000 | $445,719,000 | - | - |
| Total Debt | $650,549,000 | $623,642,000 | $102,582,000 | $104,663,000 |
| Long Term Debt And Capital Lease Obligation | $643,511,000 | $619,300,000 | $96,533,000 | $99,479,000 |
| Long Term Debt | $601,630,000 | $589,579,000 | $72,839,000 | $74,776,000 |
| Current Debt And Capital Lease Obligation | $7,038,000 | $4,342,000 | $6,049,000 | $5,184,000 |
| Current Debt | $234,000 | $436,000 | $3,046,000 | $2,202,000 |
| Other Current Borrowings | $234,000 | $436,000 | $3,046,000 | $2,202,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $845,172,000 | $873,491,000 | $213,329,000 | $226,007,000 |
| Total Non Current Liabilities Net Minority Interest | $671,413,000 | $648,084,000 | $118,467,000 | $122,197,000 |
| Other Non Current Liabilities | $20,945,000 | $22,718,000 | $14,565,000 | $15,653,000 |
| Non Current Deferred Liabilities | $6,957,000 | $6,066,000 | $7,369,000 | $7,065,000 |
| Non Current Deferred Taxes Liabilities | $6,957,000 | $6,066,000 | $7,369,000 | $7,065,000 |
| Current Liabilities | $173,759,000 | $225,407,000 | $94,862,000 | $103,810,000 |
| Payables And Accrued Expenses | $166,721,000 | $221,065,000 | $88,813,000 | $98,626,000 |
| Payables | $40,178,000 | $27,047,000 | $25,072,000 | $31,295,000 |
| Total Tax Payable | $9,664,000 | $1,609,000 | $4,571,000 | $9,081,000 |
| Income Tax Payable | $9,664,000 | $1,609,000 | $4,571,000 | $9,081,000 |
| Accounts Payable | $30,514,000 | $25,438,000 | $20,501,000 | $22,214,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $732,298,000 | $639,421,000 | $528,658,000 | $445,522,000 |
| Total Equity Gross Minority Interest | $732,298,000 | $639,421,000 | $528,658,000 | $445,522,000 |
| Stockholders Equity | $732,298,000 | $639,421,000 | $528,658,000 | $445,522,000 |
| Gains Losses Not Affecting Retained Earnings | $-9,181,000 | $-8,478,000 | $-8,624,000 | $-6,765,000 |
| Other Equity Adjustments | $-9,181,000 | $-8,478,000 | $-8,624,000 | $-6,765,000 |
| Retained Earnings | $568,787,000 | $409,268,000 | $271,723,000 | $180,337,000 |
| Long Term Equity Investment | $0 | $527,000 | $2,414,000 | $3,985,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $13,229,433 | $11,321,313 | $9,998,162 | $8,725,290 |
| Ordinary Shares Number | $47,617,691 | $48,068,881 | $48,112,069 | $47,714,912 |
| Share Issued | $60,847,124 | $59,390,194 | $58,110,231 | $56,440,202 |
| Tangible Book Value | $141,638,000 | $26,126,000 | $491,360,000 | $406,652,000 |
| Invested Capital | $1,334,162,000 | $1,229,436,000 | $604,543,000 | $522,500,000 |
| Working Capital | $360,312,000 | $264,193,000 | $283,457,000 | $214,309,000 |
| Capital Lease Obligations | $48,685,000 | $33,627,000 | $26,697,000 | $27,685,000 |
| Total Capitalization | $1,333,928,000 | $1,229,000,000 | $601,497,000 | $520,298,000 |
| Treasury Stock | $332,714,000 | $247,431,000 | $189,524,000 | $150,479,000 |
| Additional Paid In Capital | $505,400,000 | $486,056,000 | $455,077,000 | $422,423,000 |
| Capital Stock | $6,000 | $6,000 | $6,000 | $6,000 |
| Common Stock | $6,000 | $6,000 | $6,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $41,881,000 | $29,721,000 | $23,694,000 | $24,703,000 |
| Current Capital Lease Obligation | $6,804,000 | $3,906,000 | $3,003,000 | $2,982,000 |
| Current Accrued Expenses | $126,543,000 | $194,018,000 | $63,741,000 | $67,331,000 |
| Investments And Advances | $10,996,000 | $15,212,000 | $2,414,000 | $3,985,000 |
| Other Investments | $10,996,000 | $14,685,000 | $0 | - |
| Goodwill | $3,049,000 | $3,216,000 | $3,126,000 | $3,313,000 |
| Net PPE | $344,627,000 | $315,643,000 | $264,573,000 | $271,491,000 |
| Accumulated Depreciation | $-271,587,000 | $-245,298,000 | $-220,030,000 | $-199,619,000 |
| Gross PPE | $616,214,000 | $560,941,000 | $484,603,000 | $471,110,000 |
| Leases | $42,012,000 | $41,686,000 | $31,535,000 | $29,221,000 |
| Construction In Progress | $36,685,000 | $18,676,000 | $50,842,000 | $41,186,000 |
| Other Properties | $47,282,000 | $32,897,000 | $26,307,000 | $27,247,000 |
| Machinery Furniture Equipment | $313,384,000 | $291,427,000 | $237,742,000 | $235,259,000 |
| Buildings And Improvements | $169,429,000 | $168,771,000 | $130,726,000 | $130,582,000 |
| Land And Improvements | $7,422,000 | $7,484,000 | $7,451,000 | $7,615,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $39,423,000 | $24,929,000 | $18,887,000 | $17,656,000 |
| Work In Process | $32,807,000 | $30,822,000 | $37,090,000 | $33,298,000 |
| Raw Materials | $81,511,000 | $50,082,000 | $47,607,000 | $41,853,000 |
| Other Short Term Investments | $70,036,000 | $112,510,000 | $19,664,000 | $10,320,000 |
| Investmentsin Associatesat Cost | - | - | $2,414,000 | $3,985,000 |
| Minority Interest | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $172,345,000 | $145,337,000 | $65,147,000 | $70,538,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $213,386,000 | $183,503,000 | $89,181,000 | $97,994,000 |
| Cash Flow From Continuing Operating Activities | $213,386,000 | $183,503,000 | $89,181,000 | $97,994,000 |
| Operating Gains Losses | $-2,210,000 | $7,786,000 | $-878,000 | $-13,004,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-41,041,000 | $-38,166,000 | $-24,034,000 | $-27,456,000 |
| Investing Cash Flow | $-124,930,000 | $-649,116,000 | $-32,777,000 | $-28,672,000 |
| Cash Flow From Continuing Investing Activities | $-124,930,000 | $-649,116,000 | $-32,777,000 | $-28,672,000 |
| Net Other Investing Changes | $-4,119,000 | $1,390,000 | $-1,372,000 | $-2,612,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-85,458,000 | $-58,144,000 | $-39,909,000 | $-28,873,000 |
| Financing Cash Flow | $-80,953,000 | $454,093,000 | $-26,439,000 | $-37,018,000 |
| Cash Flow From Continuing Financing Activities | $-80,953,000 | $454,093,000 | $-26,439,000 | $-37,018,000 |
| Net Other Financing Charges | $-816,000 | $-25,079,000 | $-407,000 | $-56,169,000 |
| Net Common Stock Issuance | $-85,458,000 | $-58,144,000 | $-39,909,000 | $-28,873,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-8,263,000 | $-318,658,000 | $-1,781,000 | $-37,901,000 |
| Issuance Of Debt | $18,433,000 | $845,000,000 | $0 | $70,000,000 |
| Interest Paid Supplemental Data | $26,811,000 | $17,573,000 | $3,023,000 | $2,109,000 |
| Income Tax Paid Supplemental Data | $40,104,000 | $49,001,000 | $44,442,000 | $8,096,000 |
| End Cash Position | $151,844,000 | $144,531,000 | $156,333,000 | $126,588,000 |
| Beginning Cash Position | $144,531,000 | $156,333,000 | $126,588,000 | $94,507,000 |
| Effect Of Exchange Rate Changes | $-190,000 | $-282,000 | $-220,000 | $-223,000 |
| Changes In Cash | $7,503,000 | $-11,520,000 | $29,965,000 | $32,304,000 |
| Proceeds From Stock Option Exercised | $-4,849,000 | $10,974,000 | $15,658,000 | $15,925,000 |
| Common Stock Payments | $-85,458,000 | $-58,144,000 | $-39,909,000 | $-28,873,000 |
| Net Issuance Payments Of Debt | $10,170,000 | $526,342,000 | $-1,781,000 | $32,099,000 |
| Net Long Term Debt Issuance | $10,170,000 | $526,342,000 | $-1,781,000 | $32,099,000 |
| Long Term Debt Payments | $-8,263,000 | $-318,658,000 | $-1,781,000 | $-37,901,000 |
| Long Term Debt Issuance | $18,433,000 | $845,000,000 | $0 | $70,000,000 |
| Net Investment Purchase And Sale | $49,230,000 | $-105,934,000 | $-7,792,000 | $1,396,000 |
| Sale Of Investment | $126,022,000 | $38,622,000 | $27,969,000 | $18,771,000 |
| Purchase Of Investment | $-76,792,000 | $-144,556,000 | $-35,761,000 | $-17,375,000 |
| Net Business Purchase And Sale | $-129,000,000 | $-506,406,000 | $0 | $0 |
| Purchase Of Business | $-129,000,000 | $-506,406,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-41,041,000 | $-38,166,000 | $-23,613,000 | $-27,456,000 |
| Sale Of PPE | $0 | $0 | $421,000 | $0 |
| Purchase Of PPE | $-41,041,000 | $-38,166,000 | $-24,034,000 | $-27,456,000 |
| Change In Working Capital | $-14,547,000 | $-24,209,000 | $-32,177,000 | $-1,951,000 |
| Change In Other Working Capital | $6,834,000 | $-3,319,000 | $-4,555,000 | $8,349,000 |
| Change In Other Current Liabilities | $-3,750,000 | $-3,589,000 | $-3,154,000 | $-3,198,000 |
| Change In Payables And Accrued Expense | $63,563,000 | $13,237,000 | $-736,000 | $3,634,000 |
| Change In Payable | $63,563,000 | $13,237,000 | $-736,000 | $3,634,000 |
| Change In Account Payable | $63,563,000 | $13,237,000 | $-736,000 | $3,634,000 |
| Change In Prepaid Assets | $-10,726,000 | $-2,728,000 | $-1,854,000 | $2,927,000 |
| Change In Inventory | $-48,797,000 | $-1,724,000 | $-11,746,000 | $1,258,000 |
| Change In Receivables | $-21,671,000 | $-26,086,000 | $-10,132,000 | $-14,921,000 |
| Changes In Account Receivables | $-21,671,000 | $-26,086,000 | $-10,132,000 | $-14,921,000 |
| Other Non Cash Items | $6,032,000 | $11,399,000 | $466,000 | $219,000 |
| Stock Based Compensation | $24,368,000 | $20,242,000 | $17,860,000 | $18,687,000 |
| Asset Impairment Charge | $0 | $2,700,000 | $0 | $0 |
| Deferred Tax | $-16,981,000 | $-13,737,000 | $-15,751,000 | $4,209,000 |
| Deferred Income Tax | $-16,981,000 | $-13,737,000 | $-15,751,000 | $4,209,000 |
| Depreciation Amortization Depletion | $57,205,000 | $41,777,000 | $28,275,000 | $26,533,000 |
| Depreciation And Amortization | $57,205,000 | $41,777,000 | $28,275,000 | $26,533,000 |
| Amortization Cash Flow | $24,718,000 | $12,830,000 | $954,000 | $1,071,000 |
| Amortization Of Intangibles | $24,718,000 | $12,830,000 | $954,000 | $1,071,000 |
| Depreciation | $32,487,000 | $28,947,000 | $27,321,000 | $25,462,000 |
| Earnings Losses From Equity Investments | $573,000 | $1,981,000 | $1,177,000 | $208,000 |
| Gain Loss On Investment Securities | $-2,792,000 | $5,330,000 | $-2,196,000 | $27,000 |
| Net Income From Continuing Operations | $159,519,000 | $137,545,000 | $91,386,000 | $63,301,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $-13,587,000 |
| Net Short Term Debt Issuance | - | - | $0 | $-1,161,000 |
| Short Term Debt Payments | - | - | $0 | $-1,161,000 |
| Short Term Debt Issuance | - | - | $0 | $0 |